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The development of genetically modified (transgenic)
animals for the production of human recombinant ther-
apeutic proteins has been ongoing for more than 25+
years. Only recently in the last few years have products
finally been approved that can now be found commer-
cially on the market to the benefit of the medical com-
munity and patients that receive these lifesaving
therapies. rEVO Biologics has a long history in trans-
genic technology for this purpose and has been recog-
nized as the leader in this field. With the approval of
ATryn® (antithrombin alpha) by both the EMA in 2007
and the FDA in 2009, rEVO Biologics set the standard
and established significant milestones and “firsts” and is
revolutionizing the application of this technology to
recombinant therapeutic production. rEVO Biologics is
now expanding upon this success by not only furthering
the development of ATryn® into subsequent larger clini-
cal indications but also by moving additional recombi-
nant therapeutic proteins through the pipeline from
development and into early and late stage clinical trials.
The following presentation will highlight the company
history and evolution for rEVO Biologics over the years
and the developmental path for ATryn®. Specifically,
areas to be reviewed will include the technology, the
molecular biology involved, protein expression in the
mammary gland, the purification scheme, antithrombin
as a molecule and its clinical development, and the reg-
ulatory path for approval of ATryn® over the years.
Additionally, the further clinical development of ATryn®
into additional clinical indications and new proteins
being taken through this development, clinical trial eva-
luation, and regulatory approval path will be discussed.
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